AVBP · ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma reported its first quarter 2026 financial results, highlighting a net loss of $43.3 million, a significant improvement from the $64.4 million loss in the same period last year. The reduction in net loss was primarily driven by a decrease in research and development expenses, which fell to $37.6 million from $61.3 million, reflecting the completion of certain clinical activities and cost management. General and administrative expenses increased to $8.5 million from $5.5 million, likely due to expanded operations. The company ended the quarter with $326.4 million in cash and investments, providing a runway into the fourth quarter of 2027. Key pipeline updates include the expectation of topline Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in mid-2026, and the IND clearance for ARR-002, a novel dual-targeting ADC, with first patient dosing anticipated in the second half of 2026. Additionally, the partner Allist received NMPA accelerated approval for firmonertinib in second-line EGFR exon 20 insertion mutations in China. Management emphasized continued execution across registrational catalysts, with a strong balance sheet supporting operations.